Vaxxinity Announces Research Collaboration on Active Immunotherapies for Neurodegenerative Diseases with University of Florida
- None.
- None.
Insights
The partnership between Vaxxinity and the University of Florida's Center for Translational Research in Neurodegenerative Disease represents a strategic move in the biotech sector, focusing on the development of vaccines for neurodegenerative diseases. This collaboration could accelerate the research and development phase, potentially leading to breakthrough therapies. Neurodegenerative diseases, such as Alzheimer's and Parkinson's, affect millions and present a substantial market for pharmaceutical companies. A successful vaccine could significantly reduce healthcare costs associated with these diseases and provide a long-term revenue stream for Vaxxinity.
From a research perspective, the use of Vaxxinity’s synthetic peptide technology platform to target toxic proteins like beta-amyloid, tau and alpha-synuclein is noteworthy. The ability to neutralize these proteins could be a game-changer in treating neurodegenerative conditions. The preclinical studies demonstrating immunogenicity, target engagement and efficacy in animal models are promising indicators for future clinical trials. If Vaxxinity's candidates prove effective in humans, the company could secure a leading position in a new therapeutic class, with significant implications for its market valuation and investor interest.
The announcement of Vaxxinity's collaboration with UF's CTRND has the potential to influence investor sentiment positively. The backing by a state grant underscores the project's credibility and could attract additional funding or partnerships. The focus on affordable and accessible therapeutic options aligns with the current healthcare trend towards cost-effectiveness and patient accessibility. As the population ages, the demand for treatments for neurodegenerative diseases is expected to grow, presenting a substantial opportunity for Vaxxinity if their vaccine candidates reach the market.
It is important to note that the biotech sector is highly volatile and dependent on successful clinical outcomes. While the collaboration is a positive development, the actual impact on Vaxxinity's stock will largely depend on the progression to human clinical trials and eventual regulatory approval. Investors will need to monitor the outcomes of the preclinical studies closely and the company's ability to navigate the complex regulatory landscape.
From a financial perspective, the research collaboration between Vaxxinity and UF's CTRND, supported by the state of Florida, could be seen as a strategic investment in the company's pipeline. The focus on vaccines for neurodegenerative diseases taps into a high-need, high-cost area of healthcare. Vaxxinity's approach could disrupt the current treatment paradigm by potentially reducing the long-term costs of care for chronic neurodegenerative conditions. This could lead to a favorable long-term financial outlook for the company, assuming successful development and commercialization of their vaccine candidates.
However, it is crucial to consider the inherent risks of drug development, especially in the field of neurodegenerative diseases, which has seen many high-profile failures. The costs associated with R&D are substantial and the path to market is fraught with regulatory hurdles. Investors should weigh the potential for high returns against the risks of clinical trial failures. The collaboration's success could lead to future capital raises or strategic partnerships that could dilute existing shareholders but also provide necessary funding for continued development.
CAPE CANAVERAL, Fla., Jan. 30, 2024 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of medicines, today announced a research collaboration with the University of Florida’s (UF) Center for Translational Research in Neurodegenerative Disease (CTRND) to support its work on the development of vaccines for neurodegenerative diseases. The research, funded by a grant from the state of Florida, aims to further the development of Vaxxinity’s active immunotherapies to prevent and mitigate neurodegenerative diseases, having the potential to change the future of treatment by offering people an affordable and accessible therapeutic option.
“Our collaboration with the University of Florida will support the continued development of vaccines for neurodegenerative diseases affecting millions of people worldwide,” said Mei Mei Hu, CEO of Vaxxinity. “Our work with UF will drive a deeper understanding of how to neutralize toxic proteins in the brain implicated in diseases such as Alzheimer’s and Parkinson’s. This work builds upon years of research on our synthetic peptide technology platform to target endogenous proteins, and can help us to develop better candidates for neurodegenerative diseases in the future. We are not afraid to tackle the biggest challenges in science, and this collaboration is an important way we are advancing our vision to provide cheaper, safer, more convenient, and effective medicines for chronic disease to all.”
Researchers at UF will conduct a series of preclinical studies to explore the effects of Vaxxinity’s candidates for neurodegenerative disease on relevant biological targets, such as beta-amyloid, tau, and alpha-synuclein, in various in vitro and in vivo studies, including models of disease and antibody-target binding assays. This project will complement preclinical work conducted at Vaxxinity, which has already shown immunogenicity, target engagement, and efficacy in animal models of multiple neurodegenerative diseases including Alzheimer’s and Parkinson’s.
“The University of Florida’s Center for Translational Research in Neurodegenerative Disease is committed to advancing biomedical research that can make a significant impact on human health," said Matthew J. LaVoie, Ph.D., director of UF’s CTRND. “Our focus on neurodegenerative diseases like Alzheimer’s disease and Parkinson’s disease is expanding to include vaccine candidates, and we believe this partnership will drive scientific progress and create exciting and impactful new opportunities for our faculty and students. We are grateful for the state of Florida's commitment to advancing medical science for our aging population in Florida and beyond.”
Vaxxinity’s platform is designed to harness and selectively activate the immune system by overcoming immune tolerance, stimulating the production of antibodies against endogenous targets. The Company will provide materials, including candidates derived from its platform and antibodies generated by active immunotherapy treatment, to support the collaborative research at UF.
About Vaxxinity
Vaxxinity, Inc. is a purpose-driven biotechnology company committed to democratizing healthcare across the globe. The company is pioneering a new class of medicines aimed at disrupting the existing treatment paradigm for chronic disease, increasingly dominated by monoclonal antibodies, which suffer from prohibitive costs and cumbersome administration. The company’s proprietary technology platform has enabled the innovation of novel synthetic peptide immunotherapy candidates designed to bring the efficiency of vaccines to the treatment of chronic diseases, including Alzheimer’s disease, Parkinson’s disease, migraine, and hypercholesterolemia. The technology is also implemented as part of a COVID-19 vaccine program. Vaxxinity has optimized its pipeline to achieve a potentially historic, global impact on human health.
For more information about Vaxxinity, Inc., visit http://www.vaxxinity.com and follow us on social media @vaxxinity.
About University of Florida’s Center for Translational Research in Neurodegenerative Disease
The University of Florida's Center for Translational Research in Neurodegenerative Disease, known as the CTRND, is a state-of-the-art, multidisciplinary research center focused on the discovery, development and evaluation of future treatments and diagnostics for degenerative central nervous system conditions including Alzheimer's disease, amyotrophic lateral sclerosis (ALS), frontotemporal lobar degeneration (FTLD), Parkinson's disease and stroke.
Forward-looking Statements
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The use of certain words, including "believe," "may," "continue," "advancing," "will" and similar expressions, are intended to identify forward-looking statements. Forward-looking statements include statements, other than statements of historical fact, regarding, among other things: the plans for, or progress, scope, initiation, duration, enrollment, results or timing for availability of results of, development of any of Vaxxinity’s product candidates or programs; the target indication(s) for development or approval, the size, design, population, location, conduct, cost, objective, enrollment, duration or endpoints of any clinical trial, or the timing for initiation or completion of or availability or reporting of results from any clinical trial; the potential future regulatory authorization or approval and commercialization of Vaxxinity’s product candidates; the potential benefits or competitive position of any Vaxxinity product candidate or program or the commercial opportunity in any target indication; and Vaxxinity’s plans, expectations or future operations, financial position, revenues, costs or expenses. These forward-looking statements involve substantial risks and uncertainties, including statements that are based on the current expectations and assumptions of Vaxxinity’s management about the development of a new class of immunotherapeutic vaccines and the innovation and efficacy of Vaxxinity’s product candidates. Various important factors could cause actual results or events to differ materially from those that may be expressed or implied by our forward-looking statements, including, but not limited to: whether UB-311, UB-312, UB-313, VXX-401, UB-612 or any other current or future product candidate of Vaxxinity will be approved or authorized by any regulatory agency for the indications that Vaxxinity targets; any potential negative impacts of the COVID-19 pandemic, including on manufacturing, supply, conduct or initiation of clinical trials, or other aspects of Vaxxinity’s business; Vaxxinity’s product candidates may not be successful or clinical development may take longer and be more costly than anticipated; product candidates that appeared promising in earlier research and clinical trials may not demonstrate safety or efficacy in larger-scale or later clinical trials or in clinical trials for other indications; the timing for initiation or completion of, or for availability of data from, clinical trials for UB-311, UB-312, UB-313, VXX-401 or UB-612, and the outcomes of such trials; Vaxxinity’s reliance on collaborative partners and other third parties for development of its product candidates; Vaxxinity’s ability to obtain coverage, pricing or reimbursement for any approved products and acceptance from patients and physicians for any approved indications; delays or other challenges in the recruitment of patients for, or the conduct of, Vaxxinity’s clinical trials; challenges associated with supply and manufacturing activities; and Vaxxinity’s accounting policies. These and other important factors to be considered in connection with forward-looking statements are described in the "Risk Factors" section of Vaxxinity’s Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission on March 27, 2023. The forward-looking statements are made as of this date and Vaxxinity does not undertake any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
Investor Contact
Mark Joinnides
ir@vaxxinity.com
Press Contact
Jon Yu
media@vaxxinity.com
FAQ
What is the ticker symbol for Vaxxinity, Inc.?
What is the research collaboration announced by Vaxxinity, Inc.?
What is the aim of the research collaboration between Vaxxinity, Inc. and the University of Florida?
What has Vaxxinity, Inc. shown in its preclinical work related to neurodegenerative diseases?
What is Vaxxinity, Inc.'s platform designed to do?
